Antimalarial drugs work by attacking the malaria parasite at vulnerable points in its complex life cycle, which spans human liver cells, red blood cells, and the gut of a mosquito. Most current drugs target the blood stage, where the parasite feeds on hemoglobin and produces toxic waste it must neutralize to survive. Different drug classes disrupt different parts of that survival machinery, and because resistance to any single drug evolves quickly, the global standard today is combination therapy that hits the parasite from multiple angles at once. The story of how these drugs were discovered, how they work at a molecular level, and why the fight against resistance is never finished is more layered than most people realize.
Where Drugs Meet the Parasite
Malaria is caused by single-celled Plasmodium parasites, transmitted by Anopheles mosquitoes. After a mosquito bite, the parasites first travel to the liver, where they quietly multiply inside liver cells. This stage produces no symptoms. The parasites then burst out into the bloodstream, invade red blood cells, consume hemoglobin, multiply again, and rupture those cells to infect more. It is this blood stage that causes fever, chills, and potentially fatal complications. Some parasites also develop into sexual forms called gametocytes, which a feeding mosquito picks up, allowing the cycle to continue.
Different antimalarial drugs are designed to intervene at different stages. Most act on the blood stage to relieve symptoms and prevent death. A smaller group targets the liver stage, either to prevent infection in travelers or to eliminate dormant parasites that can cause relapses months later. A growing area of research focuses on drugs that can block transmission by killing gametocytes or disrupting the parasite’s development inside the mosquito. Some drugs have activity across more than one stage. Endoperoxide compounds like the synthetic molecule OZ439 inhibit gametocyte maturation and affect development in the mosquito, while lumefantrine impairs the parasite within the insect vector.1PLoS Medicine. The Activities of Current Antimalarial Drugs on the Life Cycle Stages of Plasmodium: A Comparative Study with Human and Rodent Parasites Newer experimental compounds have been identified with dual activity against blood, liver, and mosquito stages simultaneously.2Cell Host & Microbe. Plasmepsins IX and X Are Essential and Druggable Antimalarial Targets
How Quinoline Drugs Kill the Parasite
Chloroquine, the drug that dominated malaria treatment for decades, belongs to the quinoline family. These drugs exploit a fundamental problem the parasite faces: when it digests hemoglobin inside red blood cells, it releases free heme, which is highly toxic. The parasite normally survives by converting this heme into an inert crystal called hemozoin. Quinoline drugs block that crystallization process, causing toxic heme to build up and kill the parasite from the inside.
The molecular details of this blockade have been worked out with unusual precision. Chloroquine binds to the flat crystal faces of the growing hemozoin crystal, physically preventing new layers from forming. Atomic force microscopy has shown that chloroquine and related drugs adsorb onto the crystal surface, impeding growth by blocking the molecular steps where new crystal layers attach.3PubMed Central. Heme Detoxification in the Malaria Parasite: A Target for Antimalarial Drug Development A tiny amount of chloroquine can shut down crystal growth entirely, at concentrations roughly ten thousand times lower than the amount of heme the parasite is trying to process.4PubMed Central. Mechanisms of hematin crystallization and inhibition by the antimalarial drug chloroquine At higher concentrations, chloroquine also forms an insoluble complex with heme that precipitates out, further compounding the toxic damage.
Artemisinins and the Free-Radical Assault
Artemisinin, derived from the sweet wormwood plant Artemisia annua, is the backbone of modern malaria treatment. Its discovery has a remarkable backstory. In 1971, the Chinese scientist Tu Youyou was reading ancient texts by the fourth-century physician Ge Hong, who described squeezing juice from wormwood using cold water rather than the traditional boiling method. This hint that heat might destroy the active ingredient led Tu to switch to a low-temperature extraction with ether. The resulting extract, sample #191, showed complete activity against malaria in rodents and monkeys.5PubMed Central. The discovery of artemisinin and Nobel Prize in Physiology or Medicine Tu received the Nobel Prize in Physiology or Medicine in 2015.
Artemisinins work through a mechanism distinct from quinolines but, interestingly, they also end up targeting heme detoxification. The key structural feature is a peroxide bridge within the artemisinin molecule. When iron from heme or the parasite’s own iron stores comes in contact with that bridge, it breaks, generating highly reactive free radicals. First oxygen-based radicals form, then carbon-based radicals follow through a chain of electron rearrangements.6PubMed Central. Antimalarial Mechanisms and Resistance Status of Artemisinin and Its Derivatives These radicals damage proteins, lipids, and other essential molecules inside the parasite, rapidly killing it. Artemisinins are also potent inhibitors of hemozoin crystallization, with effective concentrations roughly ten times lower than most quinoline drugs.7PubMed Central. Artemisinin-Based Drugs Target the Plasmodium falciparum Heme Detoxification Pathway
This dual mechanism, free-radical damage plus hemozoin inhibition, helps explain why artemisinins kill parasites faster than almost any other antimalarial. They clear the bloodstream rapidly, often reducing parasite counts by a factor of ten thousand within a single 48-hour cycle. The tradeoff is that artemisinins are metabolized quickly, with half-lives measured in hours rather than days.
Antifolates, Mitochondrial Blockers, and Antibiotics
Not all antimalarials go after heme. Antifolate drugs like sulfadoxine and pyrimethamine target the parasite’s ability to make folate, a vitamin it needs to build DNA. These drugs inhibit two enzymes in the folate pathway, and using both together creates a synergistic effect because the parasite cannot compensate for the loss of both enzymes at once.8PubMed. Basis for antifolate action and resistance in malaria This combination remains widely used in pregnancy prevention programs across sub-Saharan Africa.
Atovaquone, the other half of the traveler’s drug Malarone (paired with proguanil), works by collapsing the parasite’s mitochondrial membrane potential. At extremely low concentrations it shuts down mitochondrial respiration. Proguanil alone does not directly affect respiration, but together the two drugs are far more effective than either alone.9PubMed Central. A Mechanism for the Synergistic Antimalarial Action of Atovaquone and Proguanil
Then there are antibiotics like doxycycline and clindamycin, which target a peculiar structure called the apicoplast. This is a remnant of an ancient algal cell that the parasite’s ancestor engulfed long ago. The apicoplast has its own small genome and makes essential molecules the parasite cannot produce any other way. Antibiotics that block protein synthesis inside the apicoplast produce a strange “delayed death” effect: treated parasites look fine through their first reproductive cycle, but their offspring inherit a crippled apicoplast and die in the second cycle.10PubMed Central. Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast The critical product the apicoplast provides turns out to be a building block for making isoprenoids; when researchers supplied this building block artificially, parasites survived even without a functioning apicoplast.11PLoS Biology. Chemical Rescue of Malaria Parasites Lacking an Apicoplast Defines Organelle Function in Blood-Stage Plasmodium falciparum Because of this delayed killing, antibiotics are too slow to use alone for acute malaria but work well for prevention in travelers.
Why Combination Therapy Is the Standard
Artemisinin-based combination therapies, universally abbreviated ACTs, are the WHO-recommended treatment for uncomplicated falciparum malaria. The logic is straightforward. Artemisinin derivatives kill parasites fast but are cleared from the body within hours. A longer-lasting partner drug, like lumefantrine, amodiaquine, mefloquine, or piperaquine, sticks around to mop up the surviving parasites over the next week or two.12PubMed. Clinical pharmacology of artemisinin-based combination therapies Using two drugs with different mechanisms also makes it harder for resistance to emerge, since a parasite would need to develop mutations against both drugs simultaneously.
That said, resistance is eroding the effectiveness of some ACTs in Southeast Asia. A newer strategy, triple ACTs, adds a third partner drug. Clinical trials show that these triple combinations are well tolerated and could significantly delay the emergence and spread of artemisinin resistance, extending the useful life of existing drugs.13PubMed Central. Preventing antimalarial drug resistance with triple artemisinin-based combination therapies
Treating Severe Malaria
When malaria progresses to its severe form, with organ failure, severe anemia, or cerebral involvement, intravenous artesunate is the drug of choice. It replaced quinine after large trials demonstrated clear survival benefits. In the AQUAMAT trial involving over 5,400 African children, mortality was about 8.5% with artesunate versus roughly 11% with quinine, a relative reduction in death of about 23%.14PubMed Central. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial A Cochrane review confirmed that artesunate reduced mortality in both adults and children compared to quinine.15PubMed Central. Artesunate versus quinine for treating severe malaria One caveat noted in children was a short-term increase in neurological side effects at hospital discharge, though most resolved at later follow-up.
Drug Resistance and How It Spreads
Chloroquine resistance, which rendered the drug useless across much of Africa and Asia by the 1980s, is mediated by mutations in a transporter protein called PfCRT. Mutant forms of this protein actively pump chloroquine out of the parasite’s digestive compartment, the very place where the drug needs to accumulate to block hemozoin formation.16PubMed Central. PfCRT and its role in antimalarial drug resistance Studies using genetically modified parasites that differed only in their PfCRT gene confirmed that these mutations are directly responsible for the drug efflux.17PubMed Central. Chloroquine resistance-conferring mutations in pfcrt give rise to a chloroquine-associated H+ leak from the malaria parasite’s digestive vacuole
Artemisinin resistance operates through a completely different mechanism. Mutations in the Kelch13 protein, first identified in the Greater Mekong Subregion, slow the rate at which artemisinins kill ring-stage parasites. This does not make the drug fail outright but delays parasite clearance, giving the partner drug a heavier burden.18PubMed Central. Role of Plasmodium falciparum Kelch 13 Protein Mutations in P. falciparum Populations from Northeastern Myanmar in Mediating Artemisinin Resistance The molecular explanation appears to be that resistant Kelch13 mutants bind heme more weakly, reducing the activation of artemisinin’s peroxide bridge and the generation of lethal free radicals.19Communications Biology. Artemisinin-resistant Plasmodium falciparum Kelch13 mutant proteins display reduced heme-binding affinity and decreased artemisinin activation When partner drugs are also compromised, treatment failures follow. Kelch13 mutations have now been detected in parts of Africa and South Asia, raising alarm about a broader spread.
Mefloquine resistance involves yet another mechanism: the parasite amplifies copies of a gene called pfmdr1. The more copies a parasite carries, the more mefloquine it can tolerate. Increased pfmdr1 copy number was the strongest predictor of mefloquine treatment failure in clinical studies and was also associated with reduced sensitivity to artesunate.20PubMed Central. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number Laboratory experiments confirmed a stepwise relationship: as mefloquine pressure increased, parasites with more gene copies were selected.21PubMed Central. Plasmodium falciparum pfmdr1 Amplification, Mefloquine Resistance, and Parasite Fitness
Preventing Relapse From Dormant Liver Parasites
Plasmodium vivax and P. ovale, two of the species that infect humans, can form dormant liver stages called hypnozoites. These can reactivate weeks or months after the initial infection, causing relapse even after the blood-stage parasites have been cleared. Eliminating hypnozoites, called “radical cure,” requires 8-aminoquinoline drugs. For decades, the only option was primaquine, taken daily for 14 days. Adherence to a two-week course is difficult, and many patients relapse because they stop early.
Tafenoquine, approved in 2018, changed the picture. It is a single-dose 8-aminoquinoline that achieves radical cure in one go.22PubMed Central. Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria A Cochrane review found that the 300 mg single dose reduced vivax recurrences by roughly two-thirds compared to no anti-hypnozoite treatment over six months.23PubMed Central. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria The catch is that both primaquine and tafenoquine can cause severe red blood cell destruction in people with G6PD deficiency, an inherited enzyme deficiency common in malaria-endemic regions. G6PD testing is mandatory before prescribing either drug.24PubMed Central. Tafenoquine and G6PD: a primer for clinicians Because tafenoquine has a long half-life, its hemolytic effects cannot be stopped by simply discontinuing the drug, making the screening requirement even more critical.
Drugs for Travelers
Travelers to malaria-endemic areas can take prophylactic drugs to prevent infection. The three main options are atovaquone-proguanil, doxycycline, and mefloquine. Each has trade-offs. Atovaquone-proguanil is well tolerated and taken daily, starting one to two days before travel. Doxycycline is inexpensive and also taken daily, but causes sun sensitivity and sometimes stomach upset; it offers the bonus of protecting against some other travel-related infections. Mefloquine is taken weekly, which appeals to long-term travelers, but has a well-documented association with neuropsychiatric side effects like vivid dreams, anxiety, and, rarely, more serious reactions.25PubMed Central. Malaria: prevention in travellers
Resistance patterns in the destination region guide the choice. Chloroquine still works in a handful of areas with low resistance, but for most of sub-Saharan Africa and Southeast Asia, atovaquone-proguanil or doxycycline are the primary recommendations.26Cochrane Database of Systematic Reviews. Drugs for preventing malaria in travellers A travel medicine clinician will also weigh pregnancy status, age, cost, and the specific itinerary when recommending a regimen.
Antimalarials in Pregnancy and for Children
Malaria in pregnancy is dangerous for both mother and fetus, increasing the risk of severe anemia, low birth weight, and stillbirth. In areas of moderate to high transmission, WHO recommends intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine, given at each scheduled antenatal visit starting in the second trimester.27PubMed Central. Drugs for Intermittent Preventive Treatment of Malaria in Pregnancy: Current Knowledge and Way Forward This is not a treatment for active malaria but a preventive measure that reduces parasite burden in the placenta.
For young children in areas with seasonal malaria, seasonal malaria chemoprevention provides monthly courses of sulfadoxine-pyrimethamine plus amodiaquine during the rainy season. A large trial combined this chemoprevention with the RTS,S malaria vaccine and found the combination was far more effective than either approach alone, reducing clinical malaria episodes by about 63% compared to chemoprevention alone and cutting severe malaria hospitalizations by roughly 70%.28PubMed. Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention Follow-up data over five years showed that this substantial protection was sustained.29The Lancet Infectious Diseases. Seasonal malaria vaccination with or without seasonal malaria chemoprevention over 5 years in children in Burkina Faso and Mali: a randomised, controlled, phase 3 trial
A Practical Detail That Matters More Than You’d Think
One of the most widely prescribed ACTs, artemether-lumefantrine, has a quirk that directly affects whether it works: lumefantrine needs fat to be absorbed properly. Taken on an empty stomach, blood levels of lumefantrine can be dramatically lower. Studies have shown that co-administering the drug with even a small amount of fat, roughly a gram or so from soy milk or oil-fortified porridge, can increase lumefantrine exposure more than fivefold.30PubMed. How much fat is necessary to optimize lumefantrine oral bioavailability? This is a real problem in resource-limited settings where patients may have little access to fatty food. Research in Uganda found that adding a small splash of vegetable oil to maize porridge achieved absorption comparable to taking the drug with milk, offering a practical workaround.31PubMed. Comparable lumefantrine oral bioavailability when co-administered with oil-fortified maize porridge or milk in healthy volunteers Without any food, lumefantrine levels may be too low to fully clear parasites, contributing to treatment failure even when the drug itself would otherwise work.
The Counterfeit Drug Problem
Fake and substandard antimalarials are a persistent threat to malaria control, particularly in sub-Saharan Africa and Southeast Asia. Counterfeit drugs may contain no active ingredient at all, while substandard ones may have degraded or insufficient amounts. Both outcomes put patients at risk of developing severe malaria and dying. Sub-therapeutic doses also create ideal conditions for drug resistance to evolve, because parasites are exposed to enough drug to select for resistance but not enough to kill them.32PubMed Central. The counterfeit anti-malarial is a crime against humanity: a systematic review of the scientific evidence
The scale of the problem is staggering. Modeling for Nigeria estimated that replacing poor-quality antimalarials with genuine ones could prevent roughly 12,300 deaths and over 33,000 hospitalizations each year. The annual economic cost of substandard and falsified antimalarials in that single country was estimated at nearly $900 million, accounting for about 11% of Nigeria’s total economic burden from malaria.33PLoS ONE. The economic impact of substandard and falsified antimalarial medications in Nigeria Cambodia has been a particular hotspot for counterfeit artemisinins, which compounds the already serious resistance problems in that region.34PubMed. Counterfeit and substandard antimalarial drugs in Cambodia
Drugs That Block Transmission
Most antimalarials are designed to treat or prevent disease in individual patients. But malaria elimination requires an additional dimension: stopping the parasite from passing between humans and mosquitoes. Transmission-blocking drugs target the sexual stages of the parasite, the gametocytes that circulate in a patient’s blood and the stages that develop inside the mosquito after a blood meal.35PubMed Central. Transmission-Blocking Strategies for Malaria Eradication: Recent Advances in Small-Molecule Drug Development The parasite population goes through dramatic bottlenecks during these transitions, making them attractive points of attack.
Primaquine in low doses already has some transmission-blocking activity by killing gametocytes. Newer compounds in development aim to target both gametocyte maturation and the parasite’s development inside the mosquito. Some researchers are exploring whether drugs could be designed to be taken up by mosquitoes during a blood meal, killing the parasite inside the insect.36PubMed. Transmission-blocking drugs for malaria elimination This is still early-stage work, but the concept reflects a shift in thinking: drugs as tools not just for individual health but for population-level control.
New Targets in the Pipeline
The push for new antimalarials has never been more urgent, given the spread of resistance. One promising target is PfATP4, a sodium pump that the parasite uses to regulate its internal salt balance and pH. Disrupting this pump kills blood-stage parasites rapidly. The most clinically advanced inhibitor, cipargamin (also called KAE609), is in late-stage trials. Researchers have recently identified additional chemical classes that hit the same target, providing backup options if resistance to cipargamin emerges.37PubMed Central. Identification of α-Azacyclic Acetamide-Based Inhibitors of P. falciparum Na(+) Pump (PfATP4) with Fast-Killing Asexual Blood-Stage Antimalarial Activity by Phenotypic Screening The broader pipeline includes compounds targeting parasite protein processing enzymes, mitochondrial electron transport, and lipid metabolism, all aiming for the kind of multi-stage activity that would simplify treatment while making resistance harder to develop.